Tacrolimus

Tacrolimus is a macrolide compound with potent immune-suppressing activity, classed among the calcineurin inhibitors ^[2]. It was isolated in 1987 by a Japanese research team from the fermentation broth of the soil bacterium Streptomyces tsukubaensis and was initially designated FK-506; its name reflects the Tsukuba region where the organism was found together with its identity as a macrolide immunosuppressant ^[1]. Early testing showed it to be more potent than the older calcineurin inhibitor ciclosporin ^[1].

The principal use of tacrolimus is to keep the immune system from rejecting transplanted organs, and it is a mainstay of regimens following liver, kidney, and heart transplantation ^[3]. A large randomized trial in liver transplant recipients found that tacrolimus-based therapy produced better outcomes over the first year than microemulsified ciclosporin, helping to establish it as a preferred agent ^[3]. In dermatology, tacrolimus is applied as an ointment for atopic dermatitis, where it offers an alternative to topical corticosteroids; systematic reviews conclude that it is effective for moderate and severe eczema, with transient burning at the application site being the most common complaint ^[4]. It has also been studied in conditions such as ulcerative colitis and certain kidney and skin disorders ^[4].

Tacrolimus is available as oral capsules, an intravenous preparation, and a topical ointment, and it appears on the World Health Organization's list of essential medicines ^[3][4]. It is a prescription-only medicine and requires careful monitoring, because systemic use can affect the kidneys, raise blood pressure and blood sugar, and increase susceptibility to infections ^[3]. Its blood levels are strongly influenced by liver enzymes of the cytochrome P450 family, so it interacts with many drugs and with grapefruit; as with other immunosuppressants, long-term systemic therapy carries an increased risk of certain cancers ^[3][4].

Topical tacrolimus is prescription only. The most common effects are a warm, burning or stinging feeling and redness at the site, especially in the first few days, plus flushing if alcohol is taken. It can make treated skin a little more prone to infections such as cold sores. It carries a boxed warning about a possible cancer risk based on theory and animal data, though large human studies have not confirmed a real increase. It is used short term and intermittently, on intact skin, and strong sun exposure should be avoided during treatment.

Tacrolimus has a narrow therapeutic index and is a substrate of both CYP3A4 and P-glycoprotein, which makes it one of the most interaction-prone drugs in routine use.

Inhibitors raise blood levels quickly and bring nephrotoxicity, tremor, headache and, at the extreme, posterior reversible encephalopathy. Azole antifungals are the strongest offenders, voriconazole, posaconazole, ketoconazole and itraconazole among them, followed by clarithromycin and erythromycin, ritonavir and cobicistat-boosted regimens, diltiazem and verapamil, and grapefruit juice.

Inducers do the opposite and are more dangerous than they look, because subtherapeutic levels mean graft rejection. Rifampin, carbamazepine, phenytoin, phenobarbital and St John's wort all substantially lower exposure.

Additive nephrotoxicity occurs with aminoglycosides, amphotericin B, cisplatin and NSAIDs. Cyclosporine both raises tacrolimus levels and compounds renal injury, and co-administration is contraindicated. Potassium-sparing diuretics add hyperkalemia.

Checking a whole stack? Run it through interactions + stacks.

Tacrolimus, originally designated FK-506, was discovered in 1984 by scientists at the Japanese company Fujisawa Pharmaceutical, who isolated it from the soil bacterium Streptomyces tsukubaensis found near Tsukuba in Japan. Screening revealed it to be a powerful immunosuppressant of the macrolide class that inhibited the activation of T lymphocytes. The transplant surgeon Thomas Starzl and colleagues pioneered its clinical use in liver transplantation in the late 1980s, and it received United States approval in 1994 under the brand name Prograf for the prevention of organ rejection.

A topical ointment formulation was later developed and approved for atopic dermatitis, providing a steroid-free option for inflamed skin. By blocking the calcium-dependent enzyme calcineurin, tacrolimus shares its core mechanism, though through a different binding protein, with the earlier drug ciclosporin. It is included on the World Health Organization's list of essential medicines.

Tacrolimus is held in high regard as a transformative immunosuppressant that helped make modern organ transplantation far more successful, and it remains a mainstay of anti-rejection regimens after liver, kidney, and other transplants. Transplant physicians value its potency and its well-understood mechanism, and its introduction contributed to marked improvements in graft survival.

In dermatology, the ointment form is appreciated as an effective, steroid-sparing treatment for eczema, particularly on delicate areas such as the face and eyelids where long-term steroid use is undesirable, and its minimal absorption into the bloodstream is a notable advantage. Honest use requires careful blood-level monitoring and attention to kidney function and infection risk when taken systemically, while the topical form can cause transient burning or itching. Its combination of proven efficacy and versatility across transplantation and skin disease has secured its lasting importance.